Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Inhibrx Biosciences (INBX) Accumulated Depreciation & Amortization (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Accumulated Depreciation & Amortization for 3 consecutive years, with $2.5 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 8.67% to $2.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.5 million through Dec 2025, up 8.67% year-over-year, with the annual reading at $2.5 million for FY2025, 8.67% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $2.5 million at Inhibrx Biosciences, up from $1.9 million in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $2.5 million in Q4 2025, with the low at $295000.0 in Q2 2023.
  • Average Accumulated Depreciation & Amortization over 3 years is $1.3 million, with a median of $1.2 million recorded in 2023.
  • The sharpest move saw Accumulated Depreciation & Amortization skyrocketed 183.39% in 2024, then grew 8.67% in 2025.
  • Over 3 years, Accumulated Depreciation & Amortization stood at $1.2 million in 2023, then skyrocketed by 91.86% to $2.3 million in 2024, then rose by 8.67% to $2.5 million in 2025.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $2.5 million, $1.9 million, and $1.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.